VBI-S
Hypovolemia due to Septic Shock
Phase 3Active
Key Facts
About Vivacelle Bio
Vivacelle Bio is a private, late-stage biotech company targeting the urgent global crisis of sepsis and hypovolemic shock with its innovative phospholipid nanoparticle platform. The company's lead asset, VBI-S, has demonstrated 100% efficacy in a Phase II trial for elevating blood pressure in septic shock patients refractory to standard therapy and is now enrolling a Phase III study. Backed by venture capital, the U.S. Department of Defense, and the National Institutes of Health, Vivacelle aims to transform critical care outcomes by addressing a profound unmet medical need with a potentially first-in-class mechanism.
View full company profile